Outlook Pharmaceuticals Report issue

For profit Phase 3
Founded: Cincinnati OH United States (2004)

Organization Overview

First Clinical Trial
2018
NCT03844074
First Marketed Drug
2008
dextroamphetamine (Dexedrine)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

OUTLOOK PHARMS | Outlook Therapeutics, Inc.

Active Ingredients

Marketed Drugs (2)

amphetamine (Adderall) (2008)

dextroamphetamine (Dexedrine) (2008)

Drugs in Phase 3 Trials (2)

bevacizumab (avastin) (4 trials)

ranibizumab (lucentis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 3)

Macular Degeneration (Phase 3)

Macular Edema (Phase 3)

Retinal Diseases (Phase 3)

Retinal Vein Occlusion (Phase 3)

Vision Disorders (Phase 3)

Vision, Low (Phase 3)

Wet Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2